Hospital supply leaders should plan for another year of low-single-digit price increases on medical-surgical products, not a return to flat costs, according to Vizient figures discussed in an October 2, 2026 interview in The Journal of Healthcare Contracting. Steven Lucio, senior principal for pharmacy solutions at Vizient, said updated projections show price growth continuing across key supply categories through mid-2027. The forecast he cited puts med-surg supply inflation at roughly 3.03 percent and pharmaceutical inflation at about 2.84 percent over the next year.
Those rates are not a spike. Lucio’s point was that they do not have to be. “Even just the fundamental pricing of supplies that our members and providers purchase are going to increase,” he said. “If you say over five years you’re increasing 3 percent every year, that’s a 15 percent increase. So, it is very substantial.”
The interview framed rising supply and drug prices as one of the main pressures on hospital and health-system margins, drawing on Vizient’s latest state-of-the-industry report. Inflation in those categories is not expected to jump into double digits. The strain comes from the increases stacking on top of higher use. An older population and higher rates of chronic disease mean more procedures and more product per case. New therapies and devices improve outcomes and add cost at the same time.
Lucio pointed to cell and gene treatments for oncology and genetic conditions, which he called “astronomically expensive,” and to theranostics, which combine diagnostic imaging with targeted treatment. Cardiovascular innovations and newer ablation approaches are also expanding, often with specialized equipment and staff. Surgical robotics and other capital-heavy tools can improve precision and still carry both the purchase price and the ongoing operating cost. “All of those elements are coming together, both in terms of the novel capabilities that patients need and the uncertainty as to what degree you as a provider will be reimbursed for using them,” he said.
The 3.03 percent and 2.84 percent figures in the October interview line up with an earlier Vizient window, not with the company’s summer outlook for calendar 2027. In February, Fierce Healthcare reported that Vizient expected average market prices across the full healthcare supply chain to rise 2.78 percent between July 2026 and June 2027, up from a prior 2.41 percent call. That forecast split a 2.32 percent average increase for medical products from a 3.85 percent increase in indirect spend and purchased services. Pharmaceutical prices, based on purchases by Vizient pharmacy program participants, were projected to change 2.84 percent in that period, down from a 3.35 percent call half a year earlier. Acute-care pharmacy spend was predicted to rise 3.03 percent and ambulatory pharmacy 2.85 percent.
The summer 2026 Spend Management Outlook, released in late July, moved the horizon to 2027 and raised several of those marks. Vizient projected a 3.39 percent average increase for the supply-chain, capital, and purchased-services categories in the analysis, and a 3.54 percent increase in pharmaceutical prices for pharmacy program participants. On its outlook page, Vizient lists medical and surgical products at 3.05 percent, up 0.02 percentage point from the prior read, with medical supplies at 3.21 percent and surgical supplies at 2.62 percent. Physician preference items are listed at 2.55 percent. Indirect spend and purchased services are the high category, at 4.73 percent, led by IT security, hardware, and software.
The October interview’s “about 3.03 percent” for med-surg supplies sits next to the summer figure of 3.05 percent for medical and surgical products. The “about 2.84 percent” for pharmaceuticals matches the February window through mid-2027, not the later 3.54 percent call for 2027. Supply teams using the interview for a budget should keep those periods separate.
Vizient’s own category notes say high-volume med-surg consumables remain exposed to raw materials, tariffs, logistics, and supply swings, even when the headline rate is near 3 percent. Surgical supplies in the summer table are the softer line, at 2.62 percent, while medical supplies are higher, at 3.21 percent. Physician preference items, including cardiology, neurology, orthopedics, and surgical services, stay in a band of roughly 2.2 to 2.9 percent. Vizient said procedural innovation and the shift in site of care still require physician alignment and utilization control, because price alone does not capture the cost of a robotics program or an implant that moves a case to an ambulatory surgery center.
Fierce Healthcare’s July account of the summer outlook quoted Vizient research and intelligence director Jeff King on a different driver of the broader 3.39 percent supply-chain call: demand tied to artificial intelligence, plus higher logistics and energy costs. Pharmacy remained large. The 3.54 percent drug projection included 3.64 percent in ambulatory settings and 2.85 percent in acute care, with specialty and complex medications at 4.04 percent. Vizient warned that utilization growth on those products can outweigh the price change.
That split is the operating issue for med-surg contracting. A 3 percent list-price move on gauze, drapes, and custom packs is manageable on a single SKU. It is not manageable if case volume is also up, preference items are not standardized, and robotics programs add service contracts on top of the disposable spend. Lucio’s five-year illustration — 3 percent a year compounding to about 15 percent — is the planning number, not the one-year bid.
Lucio said the response cannot stay inside pharmacy or inside a med-surg value-analysis committee. “Supply chain in total has to have that level of connectivity with their clinicians, with their physicians to understand how we bring these capabilities into our organization,” he said. Academic centers and large systems are expected to offer the newest therapies even when cost and operating complexity are high. He said gaps show up when supply chain, capital planning, managed care, and clinical leadership are not aligned on how a technology will be funded and staffed.
Vizient has been running joint education so pharmacy and supply chain teams, which often face the same problem in parallel, share practices with physicians and administrators. Theranostics was his example of a product that fails if it is handed to one department: imaging, pharmacy, physicians, capital equipment, and IT all have a piece. He also said new tools can cut length of stay and improve quality, but only if results are measured across service lines rather than inside one cost center.
Robert Lord, senior vice president of research and development at Vizient, told the Journal that the larger near-term use of artificial intelligence is operational. Manual data transfer, repeat documentation, confirmatory calls, prior authorization, and duplicate reporting consume time without changing the procedure. He said the shift is “from generating insight to enabling action,” and that healthcare already has enough data. The work is using it to cut friction so clinicians do the work only they can do. He also tied burnout to administrative load and said ambient documentation can reduce after-hours charting, while warning that productivity metrics built on volume will keep the burden in place if they are not changed.
Lucio said the report should tell leaders the pressure is widespread, not the result of one system’s miss. He noted that some organizations are still improving outcomes and have reduced contract-labor spending from recent peaks. He also said supply chain and pharmacy leaders need a seat with clinical and executive staff, because an aging population and a longer survival curve for complex patients will keep pushing care, and product, into community settings that now have to support higher-acuity work.
For med-surg programs, the October 2 account is a price signal and a management signal. Plan on roughly 3 percent med-surg inflation through mid-2027, treat a 15 percent five-year stack as the budget risk, and do not read the 2.84 percent drug figure as the 2027 pharmacy outlook. The control Vizient is arguing for is shared review of preference items, robotics programs, and high-cost therapies before they become separate invoices.
